LIVOSTIN
LOE ApproachingNDAOPHTHALMICSUSPENSION/DROPSPriority Review
Approved
Nov 1993
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LIVOSTIN is a small-molecule ophthalmic suspension approved in 1993 for idiopathic rhinitis, delivered as eye drops. The exact mechanism of action is not publicly documented in available data, but it is positioned as a symptomatic treatment for non-allergic rhinitis. This is an older, established product in Novartis's ophthalmology portfolio.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a stabilizing or contracting commercial footprint with potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LIVOSTIN currently has zero linked job openings, reflecting its mature, stable status with minimal growth. Working on this product offers stability and deep therapeutic knowledge of rhinitis, but limited career acceleration or expansion opportunities.
Brand ManagerProduct Manager
Worked on LIVOSTIN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.